Literature DB >> 27159986

Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.

Jean-Baptiste Davion1, M Cambron2,3, E Duhin2, A Chouraki2, A Lacour2, P Labauge4, C Carra4, X Ayrignac4, P Vermersch2.   

Abstract

We report two cases of primary progressive multiple sclerosis (PPMS) included in the INFORMS cohort, experiencing a relapse related to a single MRI gadolinium-enhancing lesion 3 months after fingolimod withdrawal. These two patients share similarities with relapsing-remitting multiple sclerosis cases described in the same situation, suggesting that the initiating process of the active demyelinating plaques is also present in PPMS, even without relapses, but may be triggered as fingolimod is withdrawn. Although the results of the INFORMS study suggest that fingolimod may not slow down the progression, some PPMS patients might still benefit from a disease-modifying treatment.

Entities:  

Keywords:  Fingolimod; INFORMS; Multiple sclerosis; Primary progressive; Relapse; Withdrawal

Mesh:

Substances:

Year:  2016        PMID: 27159986     DOI: 10.1007/s00415-016-8144-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  10 in total

1.  Natural history of multiple sclerosis: a unifying concept.

Authors:  Christian Confavreux; Sandra Vukusic
Journal:  Brain       Date:  2006-01-16       Impact factor: 13.501

2.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Francois H Jacques
Journal:  Neurology       Date:  2015-03-03       Impact factor: 9.910

3.  Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.

Authors:  A Ghezzi; M A Rocca; D Baroncini; P Annovazzi; M Zaffaroni; G Minonzio; G Comi; M Filippi
Journal:  J Neurol       Date:  2012-11-16       Impact factor: 4.849

4.  Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.

Authors:  Benjamin Berger; Annette Baumgartner; Sebastian Rauer; Irina Mader; Niklas Luetzen; Ulrich Farenkopf; Oliver Stich
Journal:  J Neuroimmunol       Date:  2015-04-07       Impact factor: 3.478

5.  Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.

Authors:  Bahia Hakiki; Emilio Portaccio; Marta Giannini; Lorenzo Razzolini; Luisa Pastò; Maria Pia Amato
Journal:  Mult Scler       Date:  2012-07-24       Impact factor: 6.312

6.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

Review 7.  Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?

Authors:  Jack Antel; Samson Antel; Zografos Caramanos; Douglas L Arnold; Tanja Kuhlmann
Journal:  Acta Neuropathol       Date:  2012-02-11       Impact factor: 17.088

8.  Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors:  Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

9.  Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

Authors:  Joachim B Havla; Hannah L Pellkofer; Ingrid Meinl; Lisa Ann Gerdes; Reinhard Hohlfeld; Tania Kümpfel
Journal:  Arch Neurol       Date:  2012-02

10.  Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Fred Lublin; David H Miller; Mark S Freedman; Bruce A C Cree; Jerry S Wolinsky; Howard Weiner; Catherine Lubetzki; Hans-Peter Hartung; Xavier Montalban; Bernard M J Uitdehaag; Martin Merschhemke; Bingbing Li; Norman Putzki; Fonda C Liu; Dieter A Häring; Ludwig Kappos
Journal:  Lancet       Date:  2016-01-28       Impact factor: 79.321

  10 in total
  2 in total

1.  Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.

Authors:  Cesar Alvarez-Gonzalez; Ashok Adams; Joela Mathews; Benjamin P Turner; Gavin Giovannoni; David Baker; Klaus Schmierer
Journal:  Ann Clin Transl Neurol       Date:  2017-05-17       Impact factor: 4.511

Review 2.  Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.

Authors:  Kerri A Schoedel; Carine Kolly; Anne Gardin; Srikanth Neelakantham; Kasra Shakeri-Nejad
Journal:  Psychopharmacology (Berl)       Date:  2021-11-13       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.